NAP1L5

Across TCGA pan-cancer cohorts, NAP1L5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAP1L5 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NAP1L5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NAP1L5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where NAP1L5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.896	0.261	<.001	10	view →
HNSC	OS	Median	All	0.903	0.755	.007	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	5	view →
LSCC	DFS	Tertile	All	0.924	0.999	.036	3	view →
GBM	OS	Median	All	0.468	0.284	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAP1L5–CCRCC (DFS)

Open the CCRCC breakdown →